| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Canada | 3 | |
| #2 | China | 3 | |
| #3 | EPO (European Patent Office) | 3 | |
| #4 | Republic of Korea | 3 | |
| #5 | WIPO (World Intellectual Property Organization) | 3 | |
| #6 | Australia | 2 | |
| #7 | Brazil | 2 | |
| #8 | United States | 2 | |
| #9 | Israel | 1 | |
| #10 | Japan | 1 | |
| #11 | Singapore | 1 | |
| #12 | Taiwan | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Peptides | |
| #3 | Medical preparations |
| # | Name | Total Patents |
|---|---|---|
| #1 | Herrmann Andreas | 22 |
| #2 | Pfizenmaier Klaus | 16 |
| #3 | Bantel Heike | 9 |
| #4 | Kontermann Roland | 7 |
| #5 | Zettlitz Kirstin | 7 |
| #6 | Grosse-Hovest Ludger | 5 |
| #7 | Scheurich Peter | 2 |
| #8 | Andreas Herrmann | 2 |
| #9 | Klaus Pfizenmaier | 2 |
| #10 | Richter Fabian | 2 |
| Publication | Filing date | Title |
|---|---|---|
| BR112020010632A2 | antibodies that specifically recognize human tumor necrosis factor 1 (hutnfr1) and its medical use | |
| BR112018070452A2 | a hutnfr1 receptor inhibitor, a pharmaceutical preparation comprising said inhibitor, a method of producing said inhibitor, use of said inhibitor in the manufacture of a product for treatment of a human individual, an isolated nucleic acid encoding said inhibitor, vector expression and host cells comprising said nucleic acid | |
| CA2891764A1 | Recombinant bispecific antibody binding to cd20 and cd95 | |
| CN103249742A | Anti-hutnfr1 antibody |